Immutep Ltd: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
The market value here is from Aug 1, 2026, more than 60 days ago: no market-data feed is connected for this exchange yet, so read the comparisons with today's price with that in mind.
Cash-flow value
Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.
Your own DCF model
A full discounted-cash-flow model of Immutep Ltd, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Biotechnology
Multiples of its companies with a market value at most 60 days old, times Immutep Ltd's own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Immutep Ltd | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 2.2× / 5.0× / 10.2× | 8.4× | revenue $7 M | $15 M to $68 M | 84 |
| Price to book | 3.1× / 4.5× / 12.9× | 0.6× | book equity $94 M | $287 M to $1.2 B | 69 |
Against its own history
Immutep Ltd's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
Price to sales
744.6×Now above its median of 412.6×, in the top quarter of its range; range 8.4× to 814.3× over 19 months.
Price to book
53.1×Now above its median of 19.9×, in the top quarter of its range; range 0.6× to 74.0× over 20 months.
As of Oct 15, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Jun 30, 2025 | $7 M | $-40 M | $-40 M | $0 M | $-40 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Jun 30, 2024 | $5 M | $-28 M | $-23 M | $0 M | $-23 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Jun 30, 2023 | $4 M | $-27 M | $-24 M | $0 M | $-24 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Jun 30, 2022 | $5 M | $-23 M | $-22 M | $0 M | $-22 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Jun 30, 2021 | $3 M | $-22 M | $-13 M | $0 M | $-13 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Jun 30, 2020 | $11 M | $-9 M | $-7 M | $0 M | $-7 M | — | SEC annual report (10-K, 20-F) |